Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Rigel Pharma (RIGL) Tops Q4 EPS by 10c
March 7, 2023 4:02 PM ESTRigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $51.3 million versus the consensus estimate of $36.52 million.
As of December 31, 2022, Rigel had cash, cash equivalents and short-term investments of $58.2 million, compared to $125.0... More
